Get the Stockscreener App
71.52
3.56%
2.46
Mirum Pharmaceuticals Inc stock is traded at $71.52, with a volume of 1.17M.
It is up +3.56% in the last 24 hours and up +37.04% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$69.06
Open:
$69.65
24h Volume:
1.17M
Relative Volume:
2.34
Market Cap:
$3.59B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-44.36
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+5.28%
1M Performance:
+37.04%
6M Performance:
+36.36%
1Y Performance:
+74.52%
1-Day Range:
$68.79
$72.08
1-Week Range:
$64.76
$72.08
52-Week Range:
$36.86
$72.08
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
71.52 | 3.35B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Can trapped investors hope for a rebound in Mirum Pharmaceuticals Inc.Weekly Market Outlook & Daily Price Action Insights - Newser
Why Mirum Pharmaceuticals Inc. stock attracts strong analyst attention2025 Big Picture & Long-Term Growth Stock Strategies - Newser
How hedge fund analytics apply to Mirum Pharmaceuticals Inc. stockJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
What to do if you’re stuck in Mirum Pharmaceuticals Inc.July 2025 Decliners & Fast Exit Strategy with Risk Control - Newser
Mirum Pharmaceuticals stock hits all-time high at 67.5 USD - Investing.com
Volume Profile Shows Strong Base for Mirum Pharmaceuticals Inc.Weekly Investment Report & Consistent Profit Focused Trading Strategies - beatles.ru
Mirum Pharmaceuticals Inc. Moves Into Overbought Range Analysts Cautious2025 Geopolitical Influence & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Mirum Pharmaceuticals’ SWOT analysis: rare disease biotech stock shows promise - Investing.com
Mirum Pharmaceuticals CFO Sells $526,960 Worth of Stock Amid Q2 Growth and Raised Price Targets - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Mirum Pharmaceuticals Insider Sold Shares Worth $2,480,000, According to a Recent SEC Filing - MarketScreener
Mirum Pharmaceuticals (NASDAQ:MIRM) PT Set at $89.00 by Stifel Nicolaus - Defense World
Mirum Pharma CEO Peetz sells $2.48 million in shares By Investing.com - Investing.com Canada
Mirum Pharma CFO Eric Bjerkholt sells $524k in stock By Investing.com - Investing.com Canada
What earnings revisions data tells us about Mirum Pharmaceuticals Inc.Forecasting Stock Moves with AI Insights - Newser
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Mirum Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingReal Trader Watchlist of Hot Stocks Released - 선데이타임즈
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 9.1% on Analyst Upgrade - Defense World
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsBest 5x Return Trade Entries - thegnnews.com
Mirum Pharmaceuticals Inc. stock momentum explainedTrade Safety Report with Pattern Insights - Newser
Stifel Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $89 - 富途牛牛
Mirum's Meteoric Surge: What's Fueling the 9.38% Intraday Rally? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Mirum’s Financial Rocket: Soaring Figures, Intriguing Questions - StocksToTrade
Mirum Soars 10% on Analyst Upgrades and Pipeline Catalysts: Is This the Start of a Biotech Breakout? - AInvest
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates - simplywall.st
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Cantor Fitzgerald Brokers Boost Earnings Estimates for MIRM - Defense World
Leerink Partnrs Has Bullish Forecast for MIRM Q3 Earnings - Defense World
HC Wainwright Issues Positive Estimate for MIRM Earnings - Defense World
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $80.00 - Defense World
Evercore ISI Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $89.00 - Defense World
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $66 to $89 - 富途牛牛
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Buys 398 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High After Earnings Beat - Defense World
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP - TipRanks
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Canada
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Aug 11 '25 |
Option Exercise |
2.94 |
40,000 |
117,440 |
178,641 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Aug 11 '25 |
Sale |
62.00 |
40,000 |
2,480,000 |
138,641 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):